Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP, regulates bone metabolism.
Didronel is indicated for the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis.
Paget's Disease: Didronel is indicated for the treatment of symptomatic Paget's disease of bone. Didronel therapy usually arrests or significantly impedes the disease process as evidenced by:
Symptomatic relief, including decreased pain and/or increased mobility (experienced by 3 out of 5 patients).
Reductions in serum alkaline phosphatase and urinary hydroxyproline levels (30% or more in 4 out of 5 patients).
Histomorphometry showing reduced numbers of osteoclasts and osteoblasts, and more lamellar bone formation.
Bone scans showing reduced radionuclide uptake at pagetic lesions.
In addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients.
In many patients, the disease process will be suppressed for a period of at least 1 year following cessation of therapy. The upper limit of this period has not been determined.
The effects of the Didronel treatment in patients with asymptomatic Paget's disease have not been studied. However, Didronel treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage, major joints, or major weight-bearing bones.
Heterotopic Ossification: Didronel is indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
Didronel reduces the incidence of clinically important heterotopic bone by about two-thirds. Among those patients who form heterotopic bone, Didronel retards the progression of immature lesions and reduces the severity by at least half. Follow-up data (at least 9 months posttherapy) suggest these benefits persist.
In total hip replacement patients, Didronel does not promote loosening of the prosthesis or impede trochanteric reattachment.
In spinal cord injury patients, Didronel does not inhibit fracture healing or stabilization of the spine.
Published Studies Related to Didronel (Etidronate)
Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke. [2010.05]
Incidence of hip fractures is high in chronically hospitalized, disabled, elderly patients after stroke. Duration of hospitalization was more than 1 year because of insufficiency of nursing homes...
Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial. [2009.02]
INTRODUCTION: The study was designed to establish the effects of HRT on osteoporosis and fractures over five years in postmenopausal women with asthma receiving regular glucocorticoids and to compare with etidronate. METHODS: Postmenopausal patients receiving inhaled and/or oral glucocorticoids were randomly assigned to HRT, cyclical etidronate, HRT plus cyclical etidronate or no treatment for five years...
Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. 
Analgesic effects of etidronate, alendronate and risedronate were compared in patients with osteoporosis and/or osteoarthritis by measuring the fall of skin impedance along with conventional subjective pain-estimation by visual rating scale (VRS). One hundred ninety-nine postmenopausal women consulting the Osteoporosis and Osteoarthritis Clinic of Katsuragi Hospital complaining of back and/or knee pain were randomly divided into four groups; Group A (49 subjects) given 5 mg/day alendronate, Group E (50 subjects) 200 mg/day etidronate, Group R (50 subjects) 2.5 mg/day risedronate and Group P no bisphosphonate...
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. [2008.03]
OBJECTIVE: To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)... CONCLUSION: Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL.
Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. [2008.01]
OBJECTIVE: To determine the efficacy and safety of intermittent cyclical etidronate therapy of up to 7 years for corticosteroid-induced osteoporosis... CONCLUSION: Our results indicate that longterm (up to 7 years) intermittent cyclical etidronate therapy is safe and effective for prevention and treatment of corticosteroid-induced osteoporosis in patients with connective tissue diseases.
Clinical Trials Related to Didronel (Etidronate)
HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids. [Completed]
To determine and compare the effects of Hormone replacement therapy (HRT), etidronate, HRT
plus etidronate and no treatment over 5 years in the prevention and treatment of
glucocorticoid-induced osteoporosis and fractures in post-menopausal women with asthma.
Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC) [Recruiting]
- Arterial Calcifications due to Deficiency in CD73 (ACDC) is a rare genetic disease.
People with ACDC develop calcium deposits in the arteries and joints of the fingers,
wrists, ankles and feet. These deposits cause severe pain in the hands and feet, even
when the person is at rest, and may lead to loss of the affected hand or foot.
Currently, there are no standard treatments for ACDC.
- Etidronate is a drug that helps to slow or stop the natural process that dissolves bone
tissue. It is approved to treat Paget s disease, a condition in which the bones are
soft and weak and may be deformed, painful, or easily broken. It is also used to treat
high blood calcium levels. Researchers want to see if it can be used to treat the
symptoms of ACDC and improve pain and blood flow in the hands and feet.
- To see if etridronate is a safe and effective treatment for ACDC.
- People between 18 and 80 years of age who have been diagnosed with ACDC.
- Participants will be screened with a physical exam and medical history. They will also
have imaging studies, including x-rays and DEXA bone scans, before starting treatment.
Blood and urine samples will be collected. An exercise tolerance test will also be
- Participants will take etridronate by mouth once a day for 14 days every 3 months. They
will be assigned an individualized 6-month drug schedule to follow. Participants
should not eat foods that are high in calcium for at least 2 hours after taking the
- Participants will have regular study visits throughout the treatment period. These
visits will involve imaging studies, full dental exams, and blood and urine tests.
Participants will also have exercise tolerance tests and arm and leg blood pressure
tests to measure pain and blood flow.
- Participants may also provide tissue samples for further study.
- Treatment will continue for up to 3 years as long as the side effects are not severe
and the condition does not become worse. Participants will have a final follow-up visit
after stopping treatment.
Vitamin K and Bone Turnover in Postmenopausal Women [Completed]
This one year study of the K vitamers phylloquinone (K1) and menatetranone (MK4) will study
supplementation effects on bone turnover and bone density. Women at least 5 years
postmenopause with normal bone density who do not use estrogen therapy or the following
medications may be eligible:
alendronate (Fosamax), risedronate (Actonel), pamidronate (Aredia), etidronate (Didronel),
zoledronate (Zometa), teriparatide (Forteo), raloxifene (Evista), tamoxifene, warfarin
(Coumadin), anti-seizure medications, prednisone, or oral steroids. Eligible subjects will
take calcium and vitamin D (Citracal) twice a day for the first two months and through-out
the study. After the first two months, subjects are randomized to the K1, MK4 or placebo
groups. Return visits occur at 1, 3, 6 and 12 months. Fasting blood and urine is collected
at each visit and bone density is performed at 3 study visits.
Bisphosphonate Biomarker Study [Recruiting]
Bisphosphonates are drugs that prevent bone loss by blocking the activity of cells that
normally resorb bone. The most common examples of these drugs are Boniva and Fosamax. These
drugs are available for oral or intravenous dosing and are prescribed at daily, weekly,
biweekly, or monthly intervals. Among the many thousands of individuals who currently take
these medications, certain individuals experience "atypical" femur fractures preceded by
prodromal pain, changes in cortical thickening of bone, or bisphosphonate related
osteonecrosis of the jaws (BRONJ). Osteonecrosis of the jaws is defined as exposed bone of
the jaws for 8 weeks or more and requires surgical treatment.
This study will attempt to identify genomic and rna biomarkers that may play a role in
differential metabolism of bisphosphonates or indicate tendency toward the severe adverse
events associated with these drugs.
Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients? [Not yet recruiting]
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women.
However, its safety and efficacy in increasing bone mineral density in chronic peritoneal
dialysis (PD) patients have not been investigated. Etidronate, another bisphosphonate, can
suppress the extent of coronary artery calcification in chronic hemodialysis patients. The
hypothesis of this study is that alendronate can increase bone mineral density and suppress
aortic and coronary artery calcification in chronic peritoneal dialysis patients.
Reports of Suspected Didronel (Etidronate) Side Effects
Femur Fracture (11),
Fracture Displacement (8),
Gait Disturbance (8),
Pain in Extremity (7),
Muscular Weakness (7),
Stress Fracture (7),
Pain (5), more >>